Marks R, Finlay A Y, Holt P J
Br J Dermatol. 1981 Jun;104(6):667-73. doi: 10.1111/j.1365-2133.1981.tb00753.x.
Twenty patients with disabling disorders of keratinization were treated with Tigason (etretinate, Ro 10-9359), an oral aromatic retinoid, and the clinical responses and the effects on the skin were monitored. Most patients showed a considerable clinical improvement within 4 weeks. Side effects, such as cheilitis, were common but mostly transient or minor. In the skin there was a decrease in glucose-6-phosphate dehydrogenase activity within the granular cell layer of the epidermis, and an increase in mean epidermal thickness and mean corneocyte area. However, there was little apparent effect on epidermal proliferation or on histological and ultrastructural appearances. These findings suggest that the drug acts at a late stage of epidermal differentiation.
20例患有致残性角化障碍的患者接受了口服芳香族维甲酸Tigason（阿维A酯，Ro 10 - 9359）治疗，并对临床反应和皮肤影响进行了监测。大多数患者在4周内临床症状有显著改善。诸如唇炎等副作用很常见，但大多是短暂的或轻微的。皮肤方面，表皮颗粒细胞层内葡萄糖 - 6 - 磷酸脱氢酶活性降低，平均表皮厚度和平均角质形成细胞面积增加。然而，对表皮增殖以及组织学和超微结构外观几乎没有明显影响。这些发现表明该药物作用于表皮分化的后期阶段。
